The FDA has granted Abiomed 510(k) clearance for its percutaneous, catheter-based Impella device providing peak flows of approximately four liters of blood per minute.

U.S. cardiologists are seeing more patients than ever before, yet performing, on average, fewer advanced nuclear tests on those patients, according to a joint survey from MedAxiom and the American Society of Nuclear Cardiology (ASNC). The survey respondents also cited a change in the approach to the delivery of cardiovascular care, as well as continued concerns about economic conditions as reasons for the decline.

Bayer HealthCare's partner, Janssen Research & Development, has submitted its reply to the complete response letter from the FDA for the use of rivaroxaban (Xarelto) 2.5 mg twice daily in combination with standard antiplatelet therapy to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).

Cancer screening guidelines influence approximately half of U.S. adults to undergo breast and prostate cancer screening, according to results of a Truven Health Analytics/NPR poll published in August.

Preoperative 3D visualization of sentinel lymph nodes (SLNs) via SPECT/CT was associated with a higher rate of detection of positive SLNs and a higher rate of disease-free survival among patients with melanoma, according to a study in the Sept. 12 issue of Journal of the American Medical Association.

A Dutch study of soldiers who have experienced combat stress has found severe stress reduces midbrain activity and has adverse effects on concentration, but most combat-related changes in that region normalize with time, according to the results published online Sept. 3 in Proceedings of the National Academy of Sciences.

Medicare beneficiaries who had more primary care physician (PCP) visits preceding a diagnosis of breast cancer had better outcomes, including greater use of mammography, reduced odds of late-stage diagnosis and lower breast cancer and overall mortality, according to a study published in the September/October issue of Annals of Family Medicine.

Texas Oncology and Baylor Health Enterprises have selected Irving-Las Colinas as the home for a $105 million proton therapy facility in the Dallas-Fort Worth Metroplex.